历经多年不懈探索，奥希替尼在 EGFR 突变 NSCLC 治疗领域不断突破，至今已 8 次荣登 NEJM，成为其传奇历程的见证。与此同时，奥希替尼的应用范围不断扩大，从晚期扩展到早期，从后线治疗走向前线治疗，从单药治疗到联合治疗，其在国内已有 4 个适应症获批上市，是目前国内适应症范围最广*的 EGFR-TKI。而且，奥希替尼是目前唯一*的一线、二线及辅助治疗适应症均纳入医保的三代 ...

Proto-oncogenes regulate cell growth; mutations convert them to oncogenes, leading to cancer by disrupting normal cell ...

Findings showed treatment with Rybrevant plus chemotherapy significantly reduced the risk of disease progression or death by 52% compared with chemotherapy.

ArriVent BioPharma is developing a treatment for non-small cell lung cancer. Click here to read more about AVBP stock and ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut ...

Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration approved RYBREVANT (amivantamab-vmjw) in combination ...

Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of ...

Black women in the US have a significantly higher risk of breast cancer mortality across all subtypes, with disparities ...

Wednesday announced the receipt of Fast Track Designation from the FDA for ATR-04, a topical treatment targeting ...

The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival ...

Some patients with non-small cell lung cancer (NSCLC) have mutations in a gene called human epidermal growth factor receptor ...